TB-500 and Wound Healing: What the FDA Briefing Document Signals

TB-500 (associated with Thymosin Beta-4) is scheduled for FDA Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026. The FDA's briefing document evaluates the peptide for wound healing.

A recovery-focused peptide under the microscope

TB-500 is frequently discussed alongside BPC-157 in recovery protocols. With a published FDA briefing document now available, the agency's scientific position on TB-500's safety and characterization is on the record ahead of the committee vote.

The essentials

• Evaluated use: wound healing.
• Reviewed on Day 1 (July 23, 2026).
• Public comment via Docket #FDA-2026-N-2979 — deadline July 9, 2026, docket closes July 22, 2026.

Whether TB-500 remains compoundable under 503A will hinge on the committee's recommendation and the FDA's subsequent determination.

This article is for educational purposes and summarizes publicly reported regulatory developments as of July 1, 2026. It is not medical, legal, or regulatory advice. FDA advisory committee reviews are evaluations, not approvals, and outcomes may change. Newtropin is a wellness marketing firm and not a licensed pharmacy.

Track Live FDA Peptide Status

Regulatory status changes as PCAC hearings and FDA determinations roll out. Bookmark our FDA Peptide Status Tracker 2026 for the latest category and PCAC updates on every peptide.